Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 24, 2011

Primary Completion Date

October 22, 2014

Study Completion Date

June 29, 2015

Conditions
Neoplasms
Interventions
DRUG

Paclitaxel

"Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles~* The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)~* Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted."

DRUG

Copanlisib (BAY80-6946)

BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles

Trial Locations (3)

10065

New York

63110

St Louis

77030

Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY